RxDoctor Payments Data

John Cox, MD

Pulmonary Disease · Lawton, OKNPI 1396763389

Payments from drug & device makers

$2,101in general payments, 2019–2025

Across 124 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$362
  • AstraZeneca$278
  • Bayer$158
  • Sunovion Pharmaceuticals Inc.$137
  • Takeda Pharmaceuticals U.S.A., Inc.$121
  • Fisher & Paykel Healthcare Inc$110
  • plus $936 from 23 others

What the payments were for

  • Food & beverage$2,08299%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,101 in reported general payments places this provider in the 45th percentile of 133 pulmonary disease providers in Oklahoma.

See all pulmonary disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$36,467
Medicare patients
347
Services billed
885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter140$117,571
Spiriva HandihalerTiotropium Bromide23$17,933
Breo ElliptaFluticasone/Vilanterol35$17,281
Spiriva RespimatTiotropium Bromide25$14,900
SymbicortBudesonide/Formoterol Fumarate35$11,936
Stiolto RespimatTiotropium Br/Olodaterol Hcl24$11,028
Albuterol Sulfate HfaAlbuterol Sulfate161$6,688
Ventolin HfaAlbuterol Sulfate55$3,725
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$2,970
Roflumilast14$1,983
Levothyroxine Sodium11$122
Azithromycin16$53
Prednisone12$22

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$362$134,852175 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$105$25,92849 claims
AstraZenecaSymbicort$278$11,93635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 133 pulmonary disease providers in Oklahoma.

Other pulmonary disease in Lawton

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →